Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.

Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PER® New York GU

Conference

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.


Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer